FDA Approved: OPSYNVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA page indicates a supplemental application (AP) for OPSYNVI, a fixed-dose combination of macitentan and tadalafil, submitted by Actelion Pharmaceuticals US, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• OPSYNVI (MACITENTAN AND TADALAFIL)

Snippet

SUPPL AP for OPSYNVI (MACITENTAN AND TADALAFIL)